Skip to main content
. 2023 Jul 11;28(11):e981–e994. doi: 10.1093/oncolo/oyad138

Table 2.

List of publications reporting the geographical prevalence of the KRAS mutation in >500 patients with colorectal cancer.

Study Country Patients testeda for KRASm (N) Study type Patients with the KRAS G12C mutation (n) KRAS G12C mutation prevalence within testeda population,
% (n/N)
Median KRAS G12C prevalence, % (n/N) Patients with KRASm (N1) KRAS G12C mutation prevalence within KRASm % (n/N1) Median KRAS G12C prevalence/region % (n/N1) KRASm prevalence % (N1/N) Median KRASm prevalence/region KRASm % (N1/N)
European Union
 Gvaldin et al (2019)23 Russia 744 Obs/NR 19 2.6 3.5
(2.6-5.0)
238 8.0 8.9
(8.0-14.0)
32.0 36.5
(32.0-39.7)
 Palomba et al (2016)24 Italy 1284 Obs/retrospective 64 5 457 14.0 35.6
 Malapelle et al (2012)25 Italy 1691 Obs/retrospective 64 3.8 671 9.5 39.7
 Marchetti et al (2011)26 Italy 2519 Obs/prospective 78 3.1 940 8.3 37.3
Intercontinental region
 Gil Ferreira at. (2014)27 Brazil 7797 Obs/retrospective 206 2.6 2.6 2623 7.9 7.9 33.6 33.6
Japan and Asia-Pacific region
 Price et al (2020)28 Australia 1605 Obs/retrospective 63 3.9 2.5
(1.5 to 4.3)
658 9.6 5.9
(3.6 to 9.6)
41.0 42.1
(35.9 to 51.5)
 Wong et al (2020)29 Australia 1308 Obs/prospective 56 4.3 674 8.3 51.5
 Li et al (2019b)30 China 526 Obs/retrospective 9 1.7 253 3.6 48.1
 Li et al (2019a)31 China 1164 Obs/retrospective 29 2.5 490 5.9 42.1
 Loong et al (2020)32 China 1114 Obs/retrospective 28 2.5 545 5.1 48.9
Luo et al 202033. China 655 Obs/retrospective 13 2.0 305 4.3 46.6
Shen et al, 201334 China 674 Obs/retrospective 10 1.5 242 4.1 35.9
Fu et al, 201935 China 5495 Obs/retrospective 127 2.3 2070 6.1 37.7
Won et al, 201736 South Korea 1092 Obs/retrospective 31 2.8 401 7.7 36.7
North America
 Nash et al (2010)37 USA 531 Obs/retrospective 15 2.8 4.1
(2.8 to 4.2)
190 7.9 10.0
(7.9 to 10.4)
35.8 39.0
(35.8 to 39.7)
 Paulino A (2014)38 US 577 Obs/retrospective 23 4.0 229 10 39.7
Maus et al (2014)39 US 838 Obs/retrospective 34 4.1 327 10.4 39.0
 Nusrat et al (202040 US 3469 Obs/retrospective 146 4.2 NR NR NR
Greater than 1 geographical region
 Smith et al (2013b)41 > 1 599 Obs/retrospective 17 2.8 2.8 258 6.6 6.6 43.1 43.1

aPatients with an evaluable test result.

Abbreviations: KRAS, Kirsten rat sarcoma virus gene; KRASm, KRAS mutation(s); KRAS G12C, KRAS with mutation at codon 12 that results in the substitution of glycine with cysteine; NR, not reported; Obs, observational; UK, United Kingdom; US, United States of America.